Resources

Clinical Trials

Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM (https://clinicaltrials.gov/ct2/show/NCT01811498),

Gamma Knife Radiation Clinical Outcomes (https://clinicaltrials.gov/ct2/show/NCT01811498),

Mayo Clinic Gamma Knife

De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma.
Shireman JM, Atashi F, Lee G, Ali ES, Saathoff MR, Park CH, Savchuk S, Baisiwala S, Miska J, Lesniak MS, James CD, Stupp R, Kumthekar P, Horbinski CM, Ben-Sahra I, Ahmed AU
Brain. 2021 May; 144(4): 1230-1246.
https://doi.org/10.1093/brain/awab020
PMID: 33855339
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.
Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, Tate M, Schwartz M, Zuckerman L, Lezon R, Lukas RV, Jovanovic B, McCortney K, Colman H, Chen S, Lai B, Antipova O, Deng J, Li L, Tommasini-Ghelfi S, Hurley LA, Unruh D, Sharma NV, Kandpal M, Kouri FM, Davuluri RV, Brat DJ, Muzzio M, Glass M, Vijayakumar V, Heidel J, Giles FJ, Adams AK, James CD, Woloschak GE, Horbinski C, Stegh AH
Sci Transl Med. 2021 Mar; 13(584):
https://doi.org/10.1126/scitranslmed.abb3945
PMID: 33692132

Articles:
New York Post (9/20), 5ALA Imaging Dye,
What is the Blood Brain Barrier? (article resource Brains for the Cure),